NEW TOOLS TO ADVANCE CNS DRUG DELIVERY
July 17, 2019
USA (United States of America)
Currently, there are more than 30 companies involved in the development of therapeutics for delivery to the brain via nasal deposition. Central nervous system (CNS) therapeutic indications include, but are not limited to, anxiety, epilepsy, Alzheimer's disease, Parkinson’s disease, migraine, multiple sclerosis and depression. In the treatment of depression, for example, nearly 300 million people of all ages, globally, are affected by major depressive disorder (MDD) and have not responded adequately to traditional therapies. Now a new esketamine nasal spray treatment has received FDA approval for MDD with imminent risk for suicide, which demonstrates continued applications for the safe and effective use of nasal sprays for these conditions. CNS diseases represent a huge emotional, financial and social burden to patients, their families, health care providers and society.